Aptinyx is a clinical-stage biopharmaceutical company that develops therapies for neurological disorders. The company's lead product candidate, NYX-2925, is a small molecule NMDA receptor modulator that is being evaluated for the treatment of chronic pain and other conditions. Aptinyx was founded in 2015 and is headquartered in Evanston, Illinois.